Kodak Pharma and Chemicals Lift Rochester Revenue
Rochester suppliers and contract manufacturers should track Kodak's shift toward pharmaceutical and specialty chemical production.
Updated on Nov. 4, 2026 in Corporate Finance
Eastman Kodak Co. reported third-quarter revenue of $276 million, up 3% from $269 million a year earlier, with growth driven by its Advanced Materials & Chemicals segment. The company's pharmaceutical manufacturing expansion at Eastman Business Park in Rochester is central to that segment's performance.
Why it matters
Kodak's results show a diversified manufacturer leaning on specialty chemicals and pharmaceutical production rather than its legacy imaging business. Management said the segment received heavy investment over the last several years and is now beginning to show returns.
Kodak reported Q3 revenue of $276 million, up 3% from $269 million a year earlier, and GAAP net income of $21 million versus $13 million in the prior-year period. The company generated $27 million in cash and employs roughly 1,300 people locally, making it the Rochester region's third-largest manufacturer.
The players
Eastman Kodak Co.
Kodak is a long-established Rochester-based manufacturer that has shifted toward specialty materials, chemicals and pharmaceutical manufacturing.
The details
Kodak's net income gain came mainly from higher gross profit and lower interest expense, partly offset by higher selling, general and administrative costs. Those SG&A increases were largely tied to higher equity compensation and changes in employee benefit accruals. The company also introduced a 0.9% sodium chloride sterile saline solution made at its Eastman Business Park facility as part of its pharmaceutical push.
Timeline
Over the last several years: Heavy investment in the Advanced Materials & Chemicals segment.
Q3 2025: The year-ago quarter used as the comparison base.
Q3 2026: Revenue, net income and cash results reported.
Remainder of 2026: Planned continued investment in core businesses.
Market Landscape
Kodak's pivot away from film-era imaging toward specialty chemicals and pharmaceutical manufacturing is now showing up in reported results after several years of heavy spending. The Rochester-area manufacturing base it anchors is being reshaped by this move into regulated pharmaceutical production.
Operators in Rochester's manufacturing and supply sectors should note that large local employers are steering spending toward specialty chemicals and pharmaceutical production, which may shift demand for contract manufacturing, packaging and compliance services. Businesses that supply or compete with these segments should review their own capacity and customer concentration in light of that shift.
The takeaway
The key operating insight is that multi-year capital investment in a new segment can take several years to reach reported earnings, so patience and cash discipline matter. Operators tracking local supplier or customer exposure should watch whether Kodak's segment growth holds in the next quarterly report.
Further reading
For more on how companies like Kodak allocate capital during a business pivot, see Corporate Finance coverage in Rochester.
Source note: This article includes information reported by Rochester Business Journal.
